Recently, molecular diagnostics has offered new techniques for detecting the most common mutations in thyroid cancer (BRAF, RAS, RET/PTC, and PAX 8/PPAR γ) in order to optimize the management of indeterminate follicular lesions and to guide the therapeutic approach more appropriately [10–13]. This evidence concerns the gene RET and thyroid cancer.